{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:07:19Z","timestamp":1780423639866,"version":"3.54.1"},"reference-count":16,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,13]]},"DOI":"10.1182\/bloodadvances.2022007708","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T19:16:33Z","timestamp":1657826193000},"page":"5124-5127","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-0655","authenticated-orcid":false,"given":"Jonathan M.","family":"Hyak","sequence":"first","affiliation":[{"name":"1Department of Medicine and Surgery, The Ohio State University Wexner Medical Center, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9910-1212","authenticated-orcid":false,"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"2Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[{"name":"2Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-0856","authenticated-orcid":false,"given":"Seema A.","family":"Bhat","sequence":"additional","affiliation":[{"name":"2Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1605-7875","authenticated-orcid":false,"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[{"name":"2Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-1000","authenticated-orcid":false,"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, The University of Cincinnati, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[{"name":"2Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4688-3780","authenticated-orcid":false,"given":"Dan","family":"Jones","sequence":"additional","affiliation":[{"name":"2Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecelia R.","family":"Miller","sequence":"additional","affiliation":[{"name":"2Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"2Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"issue":"2","key":"2022090115232938600_B1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1200\/OP.21.00258","article-title":"Frontline management of CLL in 2021","volume":"18","author":"Brem","year":"2022","journal-title":"JCO Oncol Pract."},{"issue":"5","key":"2022090115232938600_B2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.2020008502","article-title":"How I treat chronic lymphocytic leukemia after venetoclax","volume":"138","author":"Lew","year":"2021","journal-title":"Blood."},{"issue":"3","key":"2022090115232938600_B3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2019","journal-title":"Leukemia."},{"issue":"10232","key":"2022090115232938600_B4","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet."},{"issue":"36","key":"2022090115232938600_B5","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022090115232938600_B6","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"2022090115232938600_B7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol."},{"issue":"18","key":"2022090115232938600_B8","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood."},{"issue":"14","key":"2022090115232938600_B9","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"31","key":"2022090115232938600_B10","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-na\u00efve and relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J Clin Oncol."},{"issue":"34","key":"2022090115232938600_B11","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol."},{"key":"2022090115232938600_B12","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2019-127562","article-title":"Ibrutinib in combination with venetoclax decreases mitochondrial bioenergetics through the Impaired BTK, AKT and AMPK\/SIRT\/PGC-1\u03b1 signaling pathway in CLL","volume":"134","author":"Roy Chowdhury","year":"2019","journal-title":"Blood."},{"issue":"30","key":"2022090115232938600_B13","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol."},{"issue":"25","key":"2022090115232938600_B14","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.2020004782","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood."},{"issue":"4","key":"2022090115232938600_B15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1078-0432.CCR-21-1237","article-title":"Recognizing unmet need in the era of targeted therapy for CLL\/SLL: \u201cwhat\u2019s past is prologue\u201d (Shakespeare)","volume":"28","author":"Mato","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2022090115232938600_B16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood-2019-131732","article-title":"Combined ibrutinib and venetoclax in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"134","author":"Jain","year":"2019","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/17\/5124\/1917975\/advancesadv2022007708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/17\/5124\/1917975\/advancesadv2022007708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T15:25:56Z","timestamp":1662045956000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/17\/5124\/485913\/Combined-BCL2-and-BTK-inhibition-in-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":16,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,9,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007708","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}